ALGN Stock Analysis: Buy, Sell, or Hold?

ALGN - Align Technology Inc

ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
$163.03
-1.09 (-0.66%) β–Ό
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026 4d

Get Alerted When ALGN Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

πŸ’‘
Bottom Line:
βœ… BUY SIGNAL: ALGN shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$217.21
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$134.87
Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.7x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ALGN is currently trading at $163.03, which is considered fair relative to its 30-day fair value range of $159.35 to $170.45. The stock's valuation (Forward PE: 14.9) is in line with its historical norms (14.7). At these levels, the market is pricing in 0.5% annual earnings growth.

Technical Outlook: Technically, ALGN is in a strong uptrend. The price is currently testing key support at $160.66. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $183.87 (+12.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position FAIR
Fair Price Range $159.35 - $170.45
Company Quality Score 62/100 (BUY)
Volume Confirmation HIGH
Confidence Score 78.5%

All Signals

  • NEUTRAL: Price in fair range
  • BULLISH: Options cheap (IV 0th percentile)
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading below Wall St target ($183.87)
  • BULLISH: Expecting earnings turnaround to 0.5% growth with 1.8% revenue growth

Fair Price Analysis

30-Day Fair Range $159.35 - $170.45
Current vs Fair Value FAIR
Expected Move (7 Days) Β±$10.62 (6.5%)

Support & Resistance Levels

Support Level $160.66
Resistance Level $174.67
Current Trend Strong Uptrend

Fundamental Context

Forward P/E (Next Year Est.) 14.89
Wall Street Target $183.87 (+12.0%)
Revenue Growth (YoY) 1.8%
Earnings Growth (YoY) -49.7%
Profit Margin 9.5%
Valuation Premium vs History +0.5% premium
PE vs Historical 14.9 vs 14.7 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +0.5% (market-implied from PE analysis)
1-Year Target $164.94 (+1%)
2-Year Target $165.77 (+1%)
3-Year Target $166.59 (+2%)
3-Yr Target (if PE normalizes) (PE: 15β†’15) PE COMPRESSION $164.45 (+0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 22.3, Growth: 8.1%) $310.75 (+89%)
Base: (SPY PE: 14.9, Growth: 8.1%) $207.51 (+26%)
Bear: (PE: 12.7, Growth: 8.1%) $176.39 (+8%)
πŸ“ˆ Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 32.37 | Current EPS (TTM): $5.16
Bull Case $367.49 (+124%)
Analyst growth 100.0%, PE expands to 35.6
Base Case $334.08 (+104%)
Market implied 100.0%, PE stable at 32.4
Bear Case $113.59 (-31%)
Severe decline -20.0%, PE contracts to 27.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 5:55 PM ET
Data refreshes hourly during market hours. Next update: 6:55 PM
πŸ”₯ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Lisa C. McClain SELL 2025-09-11
Lisa C. McClain BUY 2025-08-04
Ro Khanna SELL 2025-08-04

Top Rated Medical Instruments & Supplies Stocks

Top-rated stocks in Medical Instruments & Supplies by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
ALC
Alcon AG
STRONG BUY
27 analysts
$92 63 BUY
ISRG
Intuitive Surgical Inc
BUY
33 analysts
$608 58 HOLD
RGEN
Repligen Corporation
STRONG BUY
19 analysts
$191 58 HOLD
RMD
ResMed Inc
BUY
19 analysts
$292 57 HOLD
COO
The Cooper Companies, Inc
BUY
19 analysts
$91 58 HOLD

Advanced ALGN Option Strategies

Professional options setups generated by AI based on today's ALGN price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ALGN

ALGN Technical Chart ALGN Price Prediction ALGN Earnings Date ALGN Investment Advisor ALGN Fair Price Analyzer ALGN Options Advisor ALGN Options Chain ALGN Options Analysis ALGN Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals